Author Archives: 瑶 翟

Over $76 billion! October Biopharma Deal Review

In October 2025, the global biopharmaceutical sector remained highly active, with innovation-driven collaborations and mergers & acquisitions continuing to heat up. Major deals were struck across diverse areas—including antibody drugs, ADCs, RNA therapeutics, AI-driven drug discovery, autoimmune diseases, gene editing, drug delivery, and neurological disorders—reflecting sustained investor and industry confidence in the biopharma landscape. The […]

Blog 2025-11-06

Meet DIMA at SAPA-China 2025!

The SAPA-China 2025 Pharmaceutical Industry Conference will be grandly held from October 31 to November 1, 2025, at the Shishan International Conference Center in Suzhou. Under the theme “Building an Innovative Ecosystem, Opening a New Era in Pharmaceuticals,” the conference will feature one main forum and 45 parallel sub-forums, bringing together nearly 400 top leaders […]

Uncategorized 2025-10-28

Hot Membrane Protein-Nanodiscs: Year-End Sale Now On!

Membrane proteins are key target families in drug discovery, including GPCRs, Claudins (CLDN), Tetraspanins, and transporters, which are involved in signal transduction and substance transport. However, their high hydrophobicity and complex structures often make them unstable in traditional systems.The Nanodisc technology encapsulates membrane proteins within a synthetic lipid bilayer, mimicking the natural membrane environment. This […]

News 2025-10-28

TSLP: A Promising Target for Opening a New Chapter in Immunotherapy

On January 10, Harbour BioMed and Kelun-Biotech out-licensed the overseas rights of their jointly developed TSLP antibody HBM9378/SKB378 to Windward Bio. The deal reached a total value of up to USD 970 million. HBM9378/SKB378 is a fully human anti-TSLP monoclonal antibody co-developed by Harbour BioMed and Kelun-Biotech, designed to regulate immune responses by inhibiting the thymic […]

Blog 2025-09-28

The New Race to Lose WeightNext Generation Targets

Weight loss isn’t just about “eating less and exercising more“; it’s also about the molecular dynamics behind it. While GLP-1 drugs have been a global hit over the past few years, the development of weight loss drugs extends far beyond this one. New metabolic targets are constantly being discovered, and research and clinical progress are […]

Blog 2025-09-24

Breaking Down WCLC 2025 The Most Talked-About Lung Cancer Targets

The 2025 World Lung Cancer Conference (WCLC) will be held by the International Association for the Study of Lung Cancer (IASLC) in Barcelona, Spain, from September 6th to 9th, 2025. As one of the most influential events in the global oncology community, WCLC provides a platform for academic exchange on the latest research findings and […]

Blog 2025-09-18

Unleash the Power of ADC Research: Eribulin IgG Labeling Reagent is Here!

In the field of cancer therapy, microtubule inhibitors are among the most classic types of cytotoxic agents. By blocking the dynamic assembly of microtubules, they directly interfere with cell division. From taxanes and vinca alkaloids to MMAE (monomethyl auristatin E), these molecules have long been indispensable weapons in the development of antibody-drug conjugates (ADCs). 1. […]

News 2025-08-27
pages-cover

Applications of Nanodiscs in Membrane Protein Research

Membrane proteins account for approximately 20-30% of proteins encoded by the human genome and play central roles in cell signaling, substance transport, and cell recognition. Aberrant expression and dysfunction of membrane proteins are closely associated with a variety of diseases, including cancer, neurological disorders, and metabolic diseases, making them key focuses in drug discovery. Among […]

Blog 2025-08-22

Emerging Chemokine Receptor CXCR7/ACKR3: A Promising Target in Disease Therapy

In recent years, the role of chemokine receptors in immune regulation, tumor development, and tissue repair has attracted increasing attention. C-X-C chemokine receptor type 7 (CXCR7), also known as ACKR3 (Atypical Chemokine Receptor 3), serves as an atypical receptor for CXCL12/CXCL11. Owing to its unique signaling mechanism and functional roles in various diseases, CXCR7 has […]

Blog 2025-08-11

Research Progress on CD20 in Autoimmune Diseases

Autoimmune diseases are a diverse and complex group of disorders characterized by immune dysregulation resulting from aberrant interactions between the innate and adaptive immune systems. Their pathogenesis is multifactorial, and the clinical manifestations are highly heterogeneous, posing significant challenges to effective treatment. Although recent advances have shed light on key pathological processes and molecular mechanisms, […]

Blog 2025-07-31